What is TNYA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.13B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for TNYA?

P/E (TTM) is n/a and 52-week range is $0.52 to $2.35 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s TNYA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for TNYA?

The company profile lists net income (TTM) near $-114M, EPS (TTM) near $-0.53 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Tenaya Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in South San Francisco, California, US, 217M shares outstanding, ISIN US87990A1060 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Tenaya Therapeutics Inc

$TNYA

Health Care · Biotechnology

IR Run Scenarios

$0.58

+6.63%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Tenaya Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for cardiovascular diseases. The company is headquartered in South San Francisco, California and currently employs 70 full-time employees. The company went IPO on 2021-07-30. Its pipeline includes TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to deliver a working MYBPC3 gene to heart muscle cells via a single intravenous infusion, increasing MyBP-C protein levels to address the underlying cause of MYBPC3-associated HCM with the aim of halting or even reversing disease after a single dose. Its MyPEAK-1 Phase I b/2 clinical trial is an ongoing, multi-center, open-label, dose-escalating study designed to assess the safety, tolerability and clinical efficacy of a one-time intravenous infusion of TN-201 gene replacement therapy. TN-401 is its AAV9-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene.

Employees

Website

www.tenayatherapeutics.com/

IPO

2021-07-30

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)